PLSE - Company ID 0001625101
The table below shows Pulse Biosciences, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.60M | -$13.52M | -$9.78M | -$6.57M | -$15.59M | -$11.69M |
| Capital expenditure | $33.00K | $45.00K | $5.00K | $39.00K | $279.00K | $51.00K |
| Investing cash flow | -$33.00K | -$45.00K | -$5.00K | -$39.00K | -$279.00K | $7.95M |
| Dividends paid | - | - | - |
Pulse Biosciences, Inc. reported operating cash flow of -$54.12M for fiscal year 2025. That is down 48.9% from -$36.34M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$8.05M (FY 2016) to -$54.12M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.21M | $14.81M | $305.00K | -$432.00K | -$65.00K | $51.16M |